--
--(--)
--
--(--)
Expected P&L on Expiry
Key Stats
0.00DAY`S RANGE0.00
0.00
0.00
--
--
--
--
--
--
--
Pricing Model
--
--
--
--
--
--
About PGEN20260417C4
Biological Technology
Precigen, Inc., an Ohio limited liability company, was founded. The company was re-registered as a Virginia corporation in 2004. The agency is a biopharmaceutical company in the commercialization stage, focusing on the advancement of precision medicines in the fields of immuno-oncology, autoimmune diseases and infectious diseases. The company relies on a series of proprietary technology platforms to develop product candidates for urgent and refractory diseases. In August 2025, its immunotherapy product received full approval from the U.S. Food and Drug Administration for the treatment of a rare chronic disease caused by human papillomavirus infection. The company maintains a rigorous attitude in product portfolio management, promotes clinical-stage projects based on preclinical data, and prioritizes strategic resource allocation.
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
